Literature DB >> 25124873

Repression of multiple CYP2D genes in mouse primary hepatocytes with a single siRNA construct.

Omaima Elraghy1, William S Baldwin.   

Abstract

The Cyp2d subfamily is the second most abun-dant subfamily of hepatic drug-metabolizing CYPs. In mice, there are nine Cyp2d members that are believed to have redundant catalytic activity. We are testing and optimizing the ability of one short interfering RNA (siRNA) construct to knockdown the expression of multiple mouse Cyp2ds in primary hepatocytes. Expression of Cyp2d10, Cyp2d11, Cyp2d22, and Cyp2d26 was observed in the primary male mouse hepatocytes. Cyp2d9, which is male-specific and growth hormone-dependent, was not expressed in male primary hepatocytes, potentially because of its dependence on pulsatile growth hormone release from the anterior pituitary. Several different siRNAs at different concentrations and with different reagents were used to knockdown Cyp2d expression. siRNA constructs designed to repress only one construct often mildly repressed several Cyp2d isoforms. A construct designed to knockdown every Cyp2d isoform provided the best results, especially when incubated with transfection reagents designed specifically for primary cell culture. Interestingly, a construct designed to knockdown all Cyp2d isoforms, except Cyp2d10, caused a 2.5× increase in Cyp2d10 expression, presumably because of a compensatory response. However, while RNA expression is repressed 24 h after siRNA treatment, associated changes in Cyp2d-mediated metabolism are tenuous. Overall, this study provides data on the expression of murine Cyp2ds in primary cell lines, valuable information on designing siRNAs for silencing multiple murine CYPs, and potential pros and cons of using siRNA as a tool for repressing Cyp2d and estimating Cyp2d's role in murine xenobiotic metabolism.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25124873      PMCID: PMC4936528          DOI: 10.1007/s11626-014-9803-9

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  42 in total

1.  Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells.

Authors:  Francesco Paduano; Raffaella Villa; Marzia Pennati; Marco Folini; Mara Binda; Maria Grazia Daidone; Nadia Zaffaroni
Journal:  Mol Cancer Ther       Date:  2006-01       Impact factor: 6.261

2.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

3.  Molecular cloning and characterization of three novel cytochrome P450 2D isoforms, CYP2D20, CYP2D27, and CYP2D28 in the Syrian hamster (Mesocricetus auratus).

Authors:  T Oka; M Fukuhara; F Ushio; K Kurose
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2000-09       Impact factor: 3.228

4.  Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model.

Authors:  Sharon L Miksys; Connie Cheung; Frank J Gonzalez; Rachel F Tyndale
Journal:  Drug Metab Dispos       Date:  2005-07-20       Impact factor: 3.922

5.  Sexually dimorphic regulation and induction of P450s by the constitutive androstane receptor (CAR).

Authors:  J P Hernandez; L C Mota; W Huang; D D Moore; W S Baldwin
Journal:  Toxicology       Date:  2008-11-11       Impact factor: 4.221

Review 6.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

Authors:  Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

7.  Sexually dimorphic P450 gene expression in liver-specific hepatocyte nuclear factor 4alpha-deficient mice.

Authors:  Christopher A Wiwi; Minita Gupte; David J Waxman
Journal:  Mol Endocrinol       Date:  2004-05-20

8.  Gene family of male-specific testosterone 16 alpha-hydroxylase (C-P-450(16) alpha) in mouse liver: cDNA sequences, neonatal imprinting, and reversible regulation by androgen.

Authors:  G Wong; K Kawajiri; M Negishi
Journal:  Biochemistry       Date:  1987-12-29       Impact factor: 3.162

Review 9.  Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.

Authors:  Vincent O Dezentjé; Henk-Jan Guchelaar; Johan W R Nortier; Cornelis J H van de Velde; Hans Gelderblom
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

10.  Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial.

Authors:  Kyung-Hoon Lee; Bryan A Ward; Zeruesenay Desta; David A Flockhart; David R Jones
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-07-05       Impact factor: 3.205

View more
  2 in total

1.  Transcriptomic analysis and plasma metabolomics in Aldh16a1-null mice reveals a potential role of ALDH16A1 in renal function.

Authors:  Georgia Charkoftaki; Ying Chen; Ming Han; Monica Sandoval; Xiaoqing Yu; Hongyu Zhao; David J Orlicky; David C Thompson; Vasilis Vasiliou
Journal:  Chem Biol Interact       Date:  2017-02-28       Impact factor: 5.192

2.  Development of Resistance to Endoplasmic Reticulum Stress-Inducing Agents in Mouse Leukemic L1210 Cells.

Authors:  Martin Cagala; Lucia Pavlikova; Mario Seres; Karolina Kadlecikova; Albert Breier; Zdena Sulova
Journal:  Molecules       Date:  2020-05-28       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.